Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290163 | 1.00 | ALDH1A1 (0.49) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL21259228 | 0.94 | HTT (0.48) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL19334136 | 0.94 | HTT (0.48) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL21755157 | 0.94 | HTT (0.48) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL19522401 | 0.94 | HTT (0.48) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL20746932 | 0.94 | HTT (0.48) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL22264520 | 0.94 | ALDH1A1 (0.54) | ALDH1A1HTTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL18816226 | 0.92 | HTT (0.47) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL5522050 | 0.91 | HTT (0.46) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL21695522 | 0.87 | TSHR (0.48) | ALDH1A1HTTLMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | ALDH1A1 4598/4885HTT 2077/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.